# Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer

> **NCT06826079** · PHASE2,PHASE3 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 80 (estimated)

## Conditions studied

- Gastric Junction Adenocarcinoma
- Gastric Cancer
- Immunotherapy
- Neoadjuvant Therapies

## Interventions

- **DRUG:** Sorbitol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06826079
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826079, "Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06826079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*